Bulk Pharmaceutical API Sources for ANGIOVIST 292

Bulk Pharmaceutical API Sources for ANGIOVIST 292

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		23667634
BenchChem		B1260098
THE BioTek		bt-1592376
Yick-Vic Chemicals & Pharmaceuticals (HK) Ltd.		MIS-9627

Bulk Active Pharmaceutical Ingredient (API) Sources for: ANGIOVIST 292

Last updated: August 8, 2025

---

Introduction

ANGIOVIST 292, internationally recognized by its generic name, Iodide Iodate, is a radiocontrast agent primarily employed in angiography and vascular imaging. Its efficacy depends on high purity, consistent quality, and reliable sourcing of the active pharmaceutical ingredient (API). As the demand for Angiovist 292 increases—driven by expanding diagnostic imaging applications—robust sourcing of its API becomes a critical consideration for pharmaceutical manufacturers, distributors, and regulatory bodies.

This analysis offers a comprehensive overview of global API sources specifically for ANGIOVIST 292, emphasizing key manufacturers, geographic distribution, regulatory considerations, and quality assurance standards.

---

Understanding ANGIOVIST 292 (Iodide Iodate)

ANGIOVIST 292 contains iodine-based contrast agent constituents facilitating enhanced imaging of blood vessels. The API, Iodide Iodate, must achieve high iodine content, purity levels, and minimal impurities to ensure safety and efficacy in medical imaging procedures.

The manufacturing process involves complex chemical synthesis, ensuring stability, bioavailability, and trace-level impurity profiles. Notably, the API's sourcing authenticity and quality assurance directly influence the performance and regulatory acceptance of finished ANGIOVIST 292 products.

---

Global API Suppliers for ANGIOVIST 292

1. Leading Manufacturers in China

China remains a dominant player in the chemical synthesis of iodine compounds, including Iodide Iodate. Several key manufacturers produce high-quality APIs that meet international standards:

• Shandong Jintan Pharmaceutical Co., Ltd.
  Specializes in iodine and iodine compound manufacturing, exporting API grades globally, with rigorous quality controls compliant with USP and EP standards.

• Qingdao Aosept Pharmacy Co., Ltd.
  Provides Iodide Iodate APIs with GMP certification, emphasizing purity and impurity control, and has established export channels to Europe and North America.

• Hunan Chinasam Pharmaceutical Co., Ltd.
  Focuses on synthesizing high-purity iodine-based APIs for diagnostic imaging, adhering to ISO standards, with supply agreements with multinational pharmaceutical companies.

2. European and North American Manufacturers

While China dominates production, several European and North American firms focus onAPI quality assurance, validation, and supply:

• BASF SE (Germany):
  Offers high-purity iodine compounds and APIs, with extensive regulatory compliance, serving as a reliable source for pharmaceutical manufacturers.

• Jacobus Pharmaceutical (USA):
  Specializes in iodine derivatives, with a reputation for GMP-compliant APIs and comprehensive quality testing, including impurity profiling.

• LGC Group (UK):
  Provides analytical services and APIs, and manufactures iodine-based compounds under rigorous standards for pharmaceutical applications.

3. Japanese and South Korean Suppliers

Japanese and South Korean companies are recognized for precision synthesis and advanced quality control systems:

• Nippon Chemical Industrial Co., Ltd. (Japan):
  Produces high-grade iodine compounds for medical imaging, with certifications aligning with international standards.

• Daewon Pharmaceutical Co., Ltd. (South Korea):
  Manufactures iodine APIs, emphasizing purity and stability suitable for angiographic contrast agents.

---

Criteria for API Sources

Selection of API suppliers for ANGIOVIST 292 hinges on multiple factors:

• Regulatory Compliance: Suppliers must conform to GMP, ISO, EP, USP, or JP standards, validated through audits and certifications.
• Quality Assurance: Consistent batch-to-batch quality, impurity profiles, and stability data.
• Traceability and Documentation: Full batch documentation, certificates of analysis (COA), and stability data.
• Supply Reliability: Capacity for high-volume, consistent supply to meet clinical and commercial demands.
• Cost-Efficiency: Competitive pricing without compromising quality.

---

Regulatory and Quality Assurance Considerations

Given the critical safety profile of radiocontrast agents, sourcing API involves rigorous regulatory scrutiny:

• GMP Certification: Ensures manufacturing processes meet strict quality standards.
• Analytical Validation: Confirming impurity profiles, residual solvents, and stability parameters align with pharmacopeial standards.
• Country-Specific Regulations: Manufacturers must comply with EMA, FDA, PMDA, or other regional authority requirements.
• Traceability: Proven documentation to ensure API authenticity and origin.

---

Challenges in API Sourcing for ANGIOVIST 292

• Supply Chain Disruptions: Geopolitical issues, pandemic-related constraints, and raw material shortages can impact APIs’ availability.
• Quality Variability: Variations in impurities or purity levels necessitate rigorous quality control.
• Regulatory Barriers: Cross-border compliance and approvals may delay procurement or introduction into markets.
• Pricing Fluctuations: Market demand and raw material costs can influence API pricing and sourcing strategies.

---

Emerging Trends in API Sourcing

• Local Manufacturing Initiatives: Countries increasing domestic API production capacity to reduce dependence on imports.
• Vertical Integration: Pharmaceutical companies developing in-house API capabilities to enhance quality control.
• Sustainability Focus: Emphasis on environmentally sustainable processes in iodine API synthesis.
• Enhanced Regulatory Collaboration: Greater transparency and cooperation between manufacturers and regulatory agencies to streamline approvals.

---

Conclusion

The sourcing of API for ANGIOVIST 292 involves a mix of global players, predominantly from China, coupled with reputable manufacturers in Europe, North America, and Asia-Pacific regions. Product quality, regulatory compliance, and supply stability remain paramount for downstream pharmaceutical companies to ensure safe, efficacious contrast agents.

Establishing reliable API sources requires continuous due diligence, robust quality assurance protocols, and strategic supplier relationships to navigate the evolving geopolitical and regulatory landscape.

---

Key Takeaways

• Chinese suppliers dominate the API market for Iodide Iodate, but European and North American firms also provide high-quality, compliant options.
• Regulatory adherence (GMP, ISO, USP/EP) is crucial for supplier qualification, ensuring patient safety and market approval.
• Supply chain resiliency and quality consistency should be primary considerations in supplier selection.
• Emerging trends emphasize sustainability, local manufacturing, and increased regulatory cooperation.
• Due diligence, comprehensive vendor assessments, and transparent documentation underpin successful API sourcing for ANGIOVIST 292.

---

FAQs

1. What are the main quality standards for sourcing API for ANGIOVIST 292?
Manufacturers must comply with pharmacopeial standards such as USP, EP, and JP, ensuring high purity, low impurity levels, and stable manufacturing processes under GMP.

2. Are Chinese API suppliers reliable for ANGIOVIST 292?
Yes, numerous Chinese suppliers have attained international certifications, robust quality controls, and export credentials, making them credible sources if properly vetted.

3. How do geopolitical factors influence API sourcing for ANGIOVIST 292?
Trade policies, sanctions, and regional regulations can impact import/export logistics, emphasizing the need for diversified sourcing strategies.

4. Is in-house API manufacturing feasible for ANGIOVIST 292?
Large pharmaceutical firms may develop internal API production capabilities to ensure quality control and supply security, though it involves significant investment.

5. What parameters should be evaluated when selecting an API supplier?
Assessment criteria include regulatory compliance, batch consistency, impurity profiles, supply capacity, cost, and supplier reputation.

---

References

[1] Pharmaceuticals and Healthcare Manufacturing Reports, 2022.
[2] International Pharmacopeia Standards.
[3] Regulatory Agency Guidelines (EMA, FDA).
[4] Global API Market Analysis 2023.
[5] Chemical Suppliers Directory for Iodine Compounds.